{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:28:14Z","timestamp":1789014494352,"version":"build-2803163510"},"reference-count":30,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T00:00:00Z","timestamp":1673568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Pharmacyclics LLC, an AbbVie Company"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Primary results from the phase 3 RESONATE-2 study demonstrated superior efficacy and tolerability with ibrutinib versus chlorambucil in patients with chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL). Here, we describe characteristics and outcomes of patients who received ibrutinib treatment for \u22655 years in RESONATE-2. Patients aged \u226565 years with previously untreated CLL\/SLL, without del(17p), were randomly assigned 1:1 to once-daily ibrutinib 420 mg until disease progression\/unacceptable toxicity (n = 136) or chlorambucil 0.5\u20130.8 mg\/kg for \u226412 cycles (n = 133). Baseline characteristics in ibrutinib-randomized patients (n = 136) were generally similar between patients on ibrutinib treatment for \u22655 years (n = 79) versus those on treatment for &lt;5 years (n = 57). In patients on ibrutinib treatment for \u22655 years, complete response rates improved over time, reaching 42% by 5 years. Estimated 7-year progression-free survival and overall survival rates were 82% and 94%, respectively. Adverse events (AEs) led to dose reductions in 16\/79 patients (20%); these AEs were resolved for 13\/16 patients (81%). AEs led to dose holds (\u22657 days) in 45\/79 patients (57%); these AEs were resolved for 43\/45 patients (96%). More than half (58%) of ibrutinib-randomized patients benefitted from ibrutinib treatment for \u22655 years regardless of baseline characteristics. Dose modification resolved AEs for most patients, thereby facilitating continued treatment.<\/jats:p>","DOI":"10.3390\/cancers15020507","type":"journal-article","created":{"date-parts":[[2023,1,16]],"date-time":"2023-01-16T04:31:32Z","timestamp":1673843492000},"page":"507","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Characteristics and Clinical Outcomes of Patients with Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma Receiving Ibrutinib for \u22655 Years in the RESONATE-2 Study"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3403-9144","authenticated-orcid":false,"given":"Jennifer A.","family":"Woyach","sequence":"first","affiliation":[{"name":"Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.","family":"Barr","sequence":"additional","affiliation":[{"name":"Wilmot Cancer Institute, University of Rochester, Rochester, NY 14642, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0064-4549","authenticated-orcid":false,"given":"Thomas J.","family":"Kipps","sequence":"additional","affiliation":[{"name":"University of California San Diego Moores Cancer Center, San Diego, CA 92037, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline C.","family":"Barrientos","sequence":"additional","affiliation":[{"name":"Mount Sinai Comprehensive Cancer Center, Miami Beach, FL 33140, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inhye E.","family":"Ahn","sequence":"additional","affiliation":[{"name":"Laboratory of Lymphoid Malignancies, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20814, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Ghia","sequence":"additional","affiliation":[{"name":"Universit\u00e0 Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, 20132 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Girardi","sequence":"additional","affiliation":[{"name":"Pharmacyclics LLC, an AbbVie Company, South San Francisco, CA 94080, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Hsu","sequence":"additional","affiliation":[{"name":"Pharmacyclics LLC, an AbbVie Company, South San Francisco, CA 94080, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandy","family":"Jermain","sequence":"additional","affiliation":[{"name":"Pharmacyclics LLC, an AbbVie Company, South San Francisco, CA 94080, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan A.","family":"Burger","sequence":"additional","affiliation":[{"name":"University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1182\/bloodadvances.2021006434","article-title":"Up to 8-year follow-up from RESONATE-2: First-line ibrutinib treatment for patients with chronic lymphocytic leukemia","volume":"6","author":"Barr","year":"2022","journal-title":"Blood Adv."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMoa1817073","article-title":"Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia","volume":"381","author":"Shanafelt","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(18)30788-5","article-title":"Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): A multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"Moreno","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Woyach, J.A., Ruppert, A.S., Heerema, N.A., Zhao, W., Booth, A.M., Ding, W., Bartlett, N.L., Brander, D.M., Barr, P.M., and Rogers, K. (2021, January 10\u201314). Long-term results of alliance A041202 show continued advantage of Ibrutinib-based regimens compared with Bendamustine plus Rituximab (BR) chemoimmunotherapy. Proceedings of the 2021 ASH Meeting and Exhibition, Atlanta, GA, USA.","DOI":"10.1182\/blood-2021-153146"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"UK CLL Forum, and Follows, G.A. (2019, January 7\u201310). UK CLL forum 5 year update on 315 relapsed refractory CLL patients treated with ibrutinib in 66 UK and Ireland centres. Proceedings of the 61st ASH Annual Meeting & Exposition, Orlando, FL, USA,.","DOI":"10.1182\/blood-2019-123199"},{"key":"ref_7","first-page":"5350","article-title":"Disease Progression on Ibrutinib Therapy Is Associated with a Poor Clinical Outcome in Chronic Lymphocytic Leukemia (CLL) Patients Managed in Standard Clinical Practice","volume":"130","author":"Akhtar","year":"2017","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ejca.2020.05.016","article-title":"Overall survival benefit of symptom monitoring in real-world patients with chronic lymphocytic leukaemia treated with ibrutinib: A FiLO group study","volume":"135","author":"Ysebaert","year":"2020","journal-title":"Eur. J. Cancer."},{"key":"ref_9","first-page":"4060","article-title":"Understanding Ibrutinib Treatment Discontinuation Patterns for Chronic Lymphocytic Leukemia","volume":"130","author":"Sharman","year":"2017","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10428194.2018.1554862","article-title":"Dose reductions in ibrutinib therapy are not associated with inferior outcomes in patients with chronic lymphocytic leukemia (CLL)","volume":"60","author":"Akhtar","year":"2019","journal-title":"Leuk. Lymphoma."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e208","DOI":"10.3324\/haematol.2018.198820","article-title":"Long-term real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia: 30-month follow up of the Swedish compassionate use cohort","volume":"104","author":"Winqvist","year":"2019","journal-title":"Haematologica"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/bjh.14540","article-title":"Comparable outcomes in chronic lymphocytic leukaemia (CLL) patients treated with reduced-dose ibrutinib: Results from a multi-centre study","volume":"181","author":"Mato","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1002\/cncr.31554","article-title":"Comorbidities predict inferior outcomes in chronic lymphocytic leukemia treated with ibrutinib","volume":"124","author":"Gordon","year":"2018","journal-title":"Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.3324\/haematol.2016.144576","article-title":"Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: Data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group","volume":"101","author":"Winqvist","year":"2016","journal-title":"Haematologica"},{"key":"ref_15","first-page":"4313","article-title":"The Impact of Front-Line Ibrutinib Dose Reduction and Interruption on Outcomes in Chronic Lymphocytic Leukemia (CLL) Patients","volume":"130","author":"Rhodes","year":"2017","journal-title":"Blood"},{"key":"ref_16","unstructured":"Dmitrieva, E., Nikitin, E., Rimashevskaya, E., and Ptushkin, V. (2020, January 19\u201320). Poor adherence to ibrutinib is not associated with adverse outcome in relapsed refreactory CLL patients. Proceedings of the EHA 2020 Virtual Meeting, Virtual."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1182\/blood.2019896688","article-title":"Clinically indicated ibrutinib dose interruptions and reductions do not compromise long-term outcomes in CLL","volume":"133","author":"Ahn","year":"2019","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1182\/blood-2016-12-737346","article-title":"Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL\/SLL","volume":"129","author":"Barr","year":"2017","journal-title":"Blood"},{"key":"ref_19","unstructured":"Pharmacyclics LLC (2022). IMBRUVICA\u00ae (Ibruztinib) Prescribing Information, Pharmacyclics LLC."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute\u2013Working Group 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"key":"ref_21","first-page":"5348","article-title":"Response assessment in chronic lymphocytic leukemia treated with novel agents causing an increase of peripheral blood lymphocytes","volume":"119","author":"Hallek","year":"2012","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"HSR22-153","DOI":"10.6004\/jnccn.2021.7275","article-title":"HSR22-153: Real-World Time to Discontinuation of First-Line Venetoclax + Obinutuzumab in Patients With Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma","volume":"20","author":"Lu","year":"2022","journal-title":"J. Nat. Comp. Cancer Net."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1080\/10428194.2021.1876863","article-title":"Outcomes in chronic lymphocytic leukemia patients on novel agents in the US Veterans Health Administration System","volume":"62","author":"Frei","year":"2021","journal-title":"Leuk. Lymphoma."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"874","DOI":"10.3324\/haematol.2017.182907","article-title":"Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: A real-world analysis","volume":"103","author":"Mato","year":"2018","journal-title":"Haematologica"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e985","DOI":"10.1016\/j.clml.2021.07.022","article-title":"Real-world characteristics and outcome of patients treated with single-agent ibrutinib for chronic lymphocytic leukemia in spain (IBRORS-LLC Study)","volume":"21","author":"Abrisqueta","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_26","first-page":"3011","article-title":"Front-Line Ibrutinib Therapy for Chronic Lymphocytic Leukemia (CLL) in the Real World: Responses, Toxicity, Outcomes and Subsequent Therapies","volume":"130","author":"Mato","year":"2017","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"4959","DOI":"10.2217\/fon-2021-0964","article-title":"Real-world ibrutinib dose reductions, holds and discontinuations in chronic lymphocytic leukemia","volume":"17","author":"Hou","year":"2021","journal-title":"Future Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1002\/cncr.30596","article-title":"Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib","volume":"123","author":"Jain","year":"2017","journal-title":"Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"UK CLL Forum (2016). Ibrutinib for relapsed\/refractory chronic lymphocytic leukemia: A UK and Ireland analysis of outcomes in 315 patients. Haematologica, 101, 1563\u20131572.","DOI":"10.3324\/haematol.2016.147900"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.clml.2018.10.005","article-title":"Ibrutinib Dose Adherence and Therapeutic Efficacy in Non-Hodgkin Lymphoma: A Single-Center Experience","volume":"19","author":"Williams","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/2\/507\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:05:38Z","timestamp":1760119538000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/2\/507"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,13]]},"references-count":30,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["cancers15020507"],"URL":"https:\/\/doi.org\/10.3390\/cancers15020507","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,13]]}}}